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ABSTRACT
Introduction. Neuroanatomic locations of gliomas may influence clinical presentations, molecular profiles, and patients’ pro-
gnoses.
Methods. We investigated our institutional cancer registry to include patients with glioma over a 10-year period. Statistical tests 
were used to compare demographic, genetic, and clinical characteristics among patients with gliomas in different locations. 
Survival analysis methods were then used to assess associations between location and overall survival in the full cohort, as well 
as in relevant subgroups.
Results. 182 gliomas were identified. Of the tumours confined to a single lobe, there were 51 frontal (28.0%), 50 temporal (27.5%), 
22 parietal (12.1%), and seven occipital tumours (3.8%) identified. Tumours affecting the temporal lobe were associated with re-
duced overall survival when compared to all other tumours (11 months vs. 13 months, log-rank p = 0.0068). In subgroup analyses, 
this result was significant for males [HR (95%CI) 2.05 (1.30, 3.24), p = 0.002], but not for females [HR (95%CI) 1.12 (0.65, 1.93), p 
= 0.691]. Out of 82 cases tested for IDH-1, 10 were mutated (5.5%). IDH-1 mutation was present in six frontal, two temporal, one 
thalamic, and one multifocal tumour. Out of 21 cases tested for 1p19q deletions, 12 were co-deleted, nine of which were frontal 
lobe tumours. MGMT methylation was assessed in 45 cases; 7/14 frontal tumours and 6/13 temporal tumours were methylated. 
Conclusion. Our results support the hypothesis that the anatomical locations of gliomas influence patients’ clinical courses. 
Temporal lobe tumours were associated with poorer survival, though this association appeared to be driven by these patients’ 
more aggressive tumour profiles and higher risk baseline demographics. Independently, female patients who had temporal lobe 
tumours fared better than males. Molecular analysis was limited by the low prevalence of genetic testing in the study sample, 
highlighting the importance of capturing this information for all gliomas. 
Importance of this study. The specific neuroanatomic location of tumours in the brain is thought to be predictive of treat-
ment options and overall prognosis. Despite evidence for the clinical significance of this information, there is relatively little 
information available regarding the incidence and prevalence of tumours in the different anatomical regions of the brain. This 
study has more fully characterised tumour prevalence in different regions of the brain. Additionally, we have analysed how this 
information may affect tumours’ molecular characteristics, treatment options offered to patients, and patients’ overall survival. 
This information will be informative both in the clinical setting and in directing future research. 
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Introduction 
The specific neuroanatomic location of tumours in the 
brain is thought to be predictive of patients’ treatment options 
and overall prognosis [1–4]. Previous studies have demonstrat-
ed links between specific types and locations of tumours and 
clinical outcomes [4]. One study noted increased survival in 
patients with frontal lobe glioblastomas compared to tempo-
ral and parietal glioblastomas, and another study noted that 
gliomas that cross the midline tend to have poorer survival 
than those that do not [1, 2]. Low grade gliomas have been 
observed to more frequently involve functional regions of the 
brain than glioblastomas, and gliomas that do involve these 
regions tend to have poorer survival [5, 6].  Some research has 
pointed toward differing molecular signals in different anatom-
ic regions of the brain as a potential mechanistic explanation 
for discrepancies in prevalence and survival [7]. 
Despite evidence for the clinical significance of this infor-
mation, there is relatively little published research regarding 
the overall prevalence of tumours in the different anatomical 
regions of the brain. One study characterising the anatomic 
locations of 331 gliomas was published in 2007, but this study 
was conducted exclusively in Finland and did not examine 
clinical or molecular correlates [8]. A more recent study 
analysed an institutional cancer registry and identified racial 
background and tumour anatomic location as prognostic 
factors for glioblastoma patients [9]. This study only included 
one subtype of glioma and did not comment on molecular 
features of the tumours. Another recent study commented on 
the molecular signals of tumours in different regions of the 
brain and their correlations with patient survival. However, 
the authors focused on diffuse glioma and not the prevalence 
of primary brain tumours in these locations [7].
We used our institutional cancer registry to re-examine the 
hypothesis that anatomic location can be a prognostic factor in 
brain tumour cases. Additionally, we were able to more fully 
characterise tumour anatomic locations for all glioma grades 
and assess their molecular signatures and clinical characteris-
tics, including overall survival (OS). We believe that reporting 
this information will help patients, healthcare providers, and 
neuro-oncology researchers better understand this disease 
and its clinical course.
Materials and methods
Study population
The Mayo Clinic Arizona Cancer Centre’s institutional 
cancer registry was examined for glioma cases presented dur-
ing a 10-year study period (2007–2017). Electronic medical 
records were reviewed to confirm that these were tissue-proven 
glioma cases as evidenced by pathology reports from surgical 
biopsy or resection. Patients for which no histopathological 
examination was completed were excluded from the study. 
Radiology reports and available CT and MRI images were 
reviewed by two members of the study team (CM and MMM) 
to record the specific neuroanatomical location of each pri-
mary tumour. Information about patient demographics (e.g. 
age, gender), clinical course, and tumour molecular biology 
was also recorded. 
Statistical analysis
Categorical variables were described as count and percent, 
while continuous variables were described by their mean, 
standard deviation, median, and range. Demographic, clinical, 
and genetic characteristics were compared between gliomas 
of different anatomical locations. For continuous variables, 
Wilcoxon Rank Sum test was used when comparing two groups 
and ANOVA f-test when comparing three or more groups. 
Fisher’s exact test was used to compare categorical variables 
between groups. Kaplan-Meier method and log-rank test were 
used to estimate and compare survival between glioma of 
certain anatomical locations at the univariate level. Multivar-
iable Cox Proportional Hazard models where then built where 
log-rank test found significant results. Multivariable models 
were adjusted on clinically relevant variables. Univariate and 
multivariable models were repeated in gender subgroups. All 
hypotheses were two-sided with p<0.05 considered statisti-
cally significant. Analyses were performed in SAS v9.4 (SAS 
Institute; Cary, NC, USA). 
Ethics
All patients included in this study signed informed consent 
to be included in the Mayo Clinic Arizona cancer registry for 
research purposes. Patients were approached for this at their 
initial presentation to the cancer centre. Patient information 
was maintained exclusively on a secure server and reviewed 
only by members of the study team. This research was approved 
by our institutional IRB. 
Results
Anatomical locations
We identified a total of 182 tissue-proven glioma cases 
during the 10-year study period (Tab. 1). The mean age of study 
subjects was 61.4 years (range 4–91), and there were 109 males 
(59.9%) vs 73 females (40.1%) in the sample. The majority of 
the paediatric patients in the registry were excluded from the 
study because this population frequently receives treatment 
without tissue diagnosis (brainstem tumours). The five paedi-
atric cases that were biopsy proven were included in our study. 
These included two thalamic tumours, one temporal lobe, one 
parietal lobe, and one frontal lobe tumour. Of the tumours that 
were located exclusively in one lobe of the brain, 51 were in the 
frontal lobe (28.02%), 50 were in the temporal lobe (27.47%), 
22 were in the parietal lobe (12.09%), and seven were in the 
occipital lobe (3.85%)(Fig. 1). Other tumours involved multi-
ple lobes of the brain, including nine fronto-parietal (4.95%), 
seven fronto-temporal (3.95%), and seven temporo-parietal 
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Table 1. Overall incidence of glioma by neuroanatomical location 












Temporal, Frontal, Corpus Callosum 2 1.1%
Temporal, Parietal, Occipital 2 1.1%
Total 182 100%
*Four cases marked ‘other’ were: parietooccipital, cerebellum, intraventricular, and corpus callosum
Figure 1. Involvement of cerebral lobes by gliomas; all gliomas af-
fecting a particular lobe were counted for their respective category. 
Tumours affecting multiple lobes were included in multiple regions 
of the chart (e.g. frontotemporal tumours were counted as both 
‘frontal’ and ‘temporal’) 
tumours (3.85%). Eleven cases were multifocal in nature and 
not assigned a specific anatomical region (6.04%), and two 
tumours affected the temporal, parietal, and occipital lobes 
simultaneously (1.10%). Seven tumours were located in the 
thalamus (3.85%), and another seven were found in the brain-
stem or other locations within the CNS (3.85%). Eventually, 
93 tumours were localised to the right side of the brain (51.1%), 
while 73 were localised to the left side (40.1%). The remaining 
8.8% were midline tumours and/or tumours that involved 
structures in both hemispheres of the brain. 
Survival analysis
Patient overall survival (OS) was analysed based on the 
anatomical locations of brain tumours. Tumours involving 
the temporal lobe were found to have a statistically significant 
reduction in overall survival when compared to all other tu-
mours without adjustment (median survival time 11 months 
vs 13 months, p = 0.0068) (Fig. 2). Subgroup analysis revealed 
a gender-based discrepancy in this finding. When analysing 
only male participants, the poorer temporal survival was sig-
nificant both univariately [HR (95%CI) 2.05 (1.30, 3.24), p = 
0.002] and after adjustment for age, grade, and surgery type 
[HR (95%CI) 1.62 (1.01, 2.61), p = 0.0475]. In the female-only 
subgroup, the relationship was never significant: univariate 
[HR (95%CI) 1.12 (0.65, 1.93), p = 0.691], multivariable [HR 
(95%CI) 0.90 (0.48, 1.68), p = 0.741] (Fig. 3).
Analysis of survival for tumours involving the frontal lobe 
vs. all other tumours was not statistically significant (median 
survival time 12 months vs. 10 months, p = 0.3). Due to the 
high occurrence of multi-lobe and multifocal tumours, overall 
survival was also assessed in the most common multi-lobe 
presentations. Tumours affecting both frontal and temporal 
lobes had poor survival outcomes compared to temporal 
lobe only (HR = 1.58, Type 3 p = 0.028), while tumours 
affecting the frontal lobe only and tumours affecting neither 
the frontal nor temporal lobes had increased overall survival 
compared to temporal lobe only (HR = 0.63 and HR = 0.72, 
Type 3 p=0.028) (Fig. 4, 5). However, this result was not 
upheld when adjusting for age, grade, and surgical approach 
(Type 3 p = 0.55). Tumour laterality was not an independent 
predictor of survival. 
Clinical characteristics 
Of 182 cases, 98 underwent neurosurgical resection of 
their tumours (53.8%), while 84 did not undergo resection and 
diagnosis was proven with an excisional biopsy (46.2%). Of the 
98 patients who underwent resective surgery, a total gross re-
section was achieved in 51 (60.7%), while the others underwent 
partial or subtotal section (39.3%). As expected, patients who 
underwent any resective surgery had a significantly improved 
median overall survival (24 months vs 6 months, p < 0.0001). 
Tumour grade at the time of diagnosis was also a statistically 
significant predictor of survival, with the 118 patients with 
grade 4 tumours at diagnosis (64.8%) having significantly 
shorter survival than those with grades 1–2 (10.4%) or grade 
3 tumours at diagnosis (22.5%) (p < 0.0001).  
Significant differences were not observed in the type of 
surgery between frontal and temporal tumour cases (Tab. 
2). Of our 51 cases confined to the frontal lobe, 26 patients 
underwent resective surgery (51.0%) and in 16 of these total 
gross resection was achieved (61.5%). Of the 50 cases confined 
to the temporal lobe, 22 underwent resective surgery (44.0%), 
and in 17 of these cases gross total resection was achieved 
(60.7%). Of the seven tumours affecting both the frontal and 
temporal lobes, none underwent resective surgery. 
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All Other 13.0 (10.0–21.0)
Any Temporal 11.0 (8.0–15.0)
Longrank P-value: 0.0068 + Censor



























Figure 2. Overall survival analysis of temporal lobe tumours vs all other tumours
Glioma subtypes 
Overall, 112 of 182 cases were glioblastoma (61.5%), 
50 cases were grade I–III astrocytoma (27.5%), nine cases were 
oligodendroma (4.9%), and the remaining 11 cases were un-
specified glioma or gliosarcoma (6.0%). The non-glioblastoma 
astrocytoma cases included 37 grade III and 13 grade I–II. As 
expected, glioblastoma patients had significantly poorer sur-
vival than astrocytoma and other tumour types (p < 0.0001), 
however this seems to be driven by underlying differences in 
patient age, grade at diagnosis, and surgical approach (adjusted 
p-value = 0.128).
Differences were observed between the types of tumour 
identified at different anatomical locations. Of the 50 tumours 
confined to the temporal lobe, 37 of them were glioblastoma 
(74.0%) while five were grade III astrocytoma (10.0%), two 
were grade I–II astrocytoma (4.0%) and one was oligoden-
droma (2.0%). Of the 51 tumours confined to the frontal 
lobe, 28 were glioblastoma (54.9%) while 11 were grade III 
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Overall survival (OS) results
Glioma Location Median (95% CI)
All Other 13.0 (8.0–27.0)
Any Temporal 12.0 (8.0–29.0)
Longrank P-value: 0.6834 + Censor
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AnyTemporal 20/25 12.0  
(8.0–29.0)
Reference
1Kaplan-Meier method; 2Cox model, 3Logrank test, *Wald Chi-Square test
A
B
Figure 3. Subgroup analysis showing survival in (A) male participants only and (B) female participants only
astrocytoma (21.2%), three were grade I–II astrocytoma 
(5.9%), and six were oligodendroma (11.8%). 
Genetics
We collected the available data on the presence of 
IDH1 mutations, 1p19q deletion, ATRX presence/absence, 
and MGMT methylation (Tab. 3). Due to the relatively 
recent advent of clinical genomics, there was a limited 
amount of data available. IDH1 mutation/non-mutation was 
the most frequently reported piece of genomic data, with 
82 cases (45.1%) having this information available. Of these 
82, 72 cases (87.8%) were IDH1 non-mutated and the other 
10 (12.2%) were mutated (Tab. 4). Six of the 10 reported 
IDH1 mutations were found in frontal lobe tumours, with 
the other four spread across temporal, thalamic, and other 
tumours. The 72 reported IDH-1 non-mutated tumours 
were located in the following regions: 20 temporal lobe 
(27.8%), 18 frontal lobe (25.0%), nine parietal lobe (12.5%), 
four occipital lobe (5.5%), two thalamic (2.8%), and 19 mul-
tifocal/other (26.4%). The presence of IDH-1 mutation 
conferred a statistically significant overall survival benefit 
(HR = 0.18, p = 0.007). This mutation was present in 4% 
of our temporal lobe cases, compared to 12% of our frontal 
lobe cases. 
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Figure 4. Overall survival analysis of frontal lobe tumours vs all other tumours
1p19q results were reported for 21 of our 182 patients. 12 of 
these 21 patients had the 1p19q deletion, and nine of those 
deletions were found in tumours confined to the frontal lobe. 
ATRX presence was tested in 42 of our 182 cases. ATRX was 
present in 40 of these 42 cases. Finally, MGMT methylation 
was tested in 47 of the 182 cases, with 22 cases showing meth-
ylation, 23 cases lacking methylation, and two cases showing 
indeterminate results.  Due to small sample sizes, statistical 
tests were not conducted for 1p19q, ATRX, or MGMT results. 
Discussion
This study analysed 182 tissue-proven glioma cases seen at 
our institution over a 10-year period. In general, tumours were 
more likely to be found in the right brain (51.1%) compared 
to the left (40.1%). This replicates findings from a previous 
epidemiologic study [8]. Two thirds of these gliomas (66.5%) 
involved the frontal lobe, the temporal lobe, or both. The 
remaining tumours were spread among the other lobes of 
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Figure 5. Analysis of overall survival by location (temporal vs frontal vs both vs neither/other)
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Table 2. Surgical treatment modality by glioma location 
Location Total gross resection Subtotal/partial resection Excisional biopsy Total
Brainstem 0 (0.0%) 1 (33.3%) 2  (66.7%) 3
Frontal 16 (31.4%) 10 (19.6%) 25 (49.0%) 51
Frontoparietal 2 (22.2%) 1 (11.1%) 6 (66.7%) 9
Frontotemporal 0 (0.0%) 0 (0.0%) 7 (100.0%) 7
Occipital 3 (42.9%) 1 (14.2%) 3 (42.9%) 7
Other* 1 (25.0%) 1 (25.0%) 2 (50.0%) 4
Multifocal 0 (0.0%) 1 (9.1%) 10 (90.9%) 11
Parietal 7 (31.8%) 5 (22.7%) 10 (45.5%) 22
Temporal 17 (34.0%) 11 (22.0%) 22 (44.0%) 50
Temporal, Frontal, Corpus Callosum 0 (0.0%) 0 (0.0%) 2 (100.0%) 2
Temporal, Parietal, Occipital 2 (100.0%) 0 (0.0%) 0 (0.0%) 2
Temporoparietal 3 (42.8%) 2 (28.6%) 2 (28.6%) 7
Thalamus 0 (0.0%) 0 (0.0%) 7 (100.0%) 7
Total 51 (28.0%) 33 (18.1%) 98 (53.9%) 182
*Four cases marked ‘other’ were: parietooccipital, cerebellum, intraventricular, and corpus callosum    
Table 3. Glioma molecular characteristics 
 Astrocytoma  
grades I -II (N = 13) 
Astrocytoma 







IDHI    
    Mutated 1 (20.0%) 3 (15.0%) 1 (2.0%) 5 (62.5%) 10 (12.2%)
    Non-mutated 4 (80.0%) 17 (85.0%) 48 (98.0%) 3 (37.5%) 72 (87.8%)
    Not tested 8 17 63 12 100
1p19Q    
    Deleted 0 (0.0%) 2 (50.0%) 1 (20.0%) 9 (81.8%) 12 (57.1%)
    Non-deleted 1 (100.0%) 2 (50.0%) 4 (80.0%) 2 (18.2%) 9 (42.9%)
    Not tested 12 33 107 9 161
ATRX    
    Present 4 (100.0%) 8 (88.9%) 25 (92.6%) 3 (100.0%) 40 (93.0%)
    Absent 0 (0.0%) 0 2 (7.4%) 0 (0.0%) 2 (4.7%)
    Indeterminate 0 (0.0%) 1 (11.1%) 0 (0.0%) 0 (0.0%) 1 (2.3%)
    Not tested 9 28 85 17 139
MGMT    
    Methylated 0 (0.0%) 1 (25.0%) 21 (51.2%) 0 (0.0%) 22 (46.8%)
    Un-methylated 1 (100.0%) 3 (75.0%) 18 (43.9%) 1 (100.0%) 23 (48.9%)
    Indeterminate 0 (0.0%) 0 (0.0%) 2 (4.9%) 0 (0.0%) 2 (4.3%)
    Not tested 12 33 71 19 135
the brain, the thalamus, and the brainstem. Survival analysis 
showed the poorest overall survival in gliomas affecting the 
temporal lobe.  Tumours affecting the temporal lobe were 
more likely to be WHO grade 4/glioblastomas, less likely 
to have IDH-1 mutations, and were associated with higher 
mean and median age at diagnosis. Patients with temporal 
lobe tumours and patients with frontal lobe tumours were 
equally likely to undergo resective surgery, so differences 
in treatment modality alone do not explain the difference 
in survival. Interestingly, subgroup analysis revealed the 
association between temporal location and poorer survival 
to be true only in males, both before and after adjustment 
for grade, age, and surgical resection. Based on this data we 
can conclude that in this data set, patients with temporal 
lobe gliomas had poorer overall survival than patients with 
frontal (and other location) gliomas. This finding appears to 
be driven by the molecular and clinical characteristics of these 
tumours and patients. 
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Table 4. Frequency of IDH-1 mutation by tumour type  
IDH-1 mutation frequency
Mutated Non-mutated Total
Glioblastoma 1 (2.0%) 48 (98.0%) 49 (59.7%)
Astrocytoma 4 (16.0%) 21 (84.0%) 25 (30.5%)
Other 5 (62.5%) 3 (37.5%) 8 (9.8%)
Total 10 (12.2%) 2 (87.8%) 82 (100%)
The results of our study provide further evidence for 
the hypothesis that gliomas preferentially arise in particular 
neuroanatomical locations, and that these locations have 
implications for clinical outcomes. 
Our finding that the frontal and temporal lobes are the 
most common primary sites of gliomas replicates previous 
analyses of glioma by lobe of the brain [2, 8]. It is also of in-
terest that the three most frequent locations for gliomas were 
associated with frontal, temporal, and parietal lobes (37.8%, 
37.3%, 21.9% respectively), but not with occipital lobe (total 
of 4.9%). This distribution is not attributable to differences 
in volumes (and hence differences in the simple probability 
of glioma occurrence) among these structures. While human 
occipital lobe volume equals approximately only half of the 
volume of frontal lobe, the frequencies of glioma incidents 
in these two structures differ by a factor of 7.7, as indicated 
by our data. Furthermore, the negligible difference in the 
volume of parietal and occipital lobes cannot account for 
the 7.6-fold difference in glioma frequency between these 
two lobes [8, 10]. At the same time, the seemingly smaller 
incidence of gliomas in parietal lobes is actually higher than 
the incidence in frontal lobes when corrected for the volumes 
of the structures.  
A plausible explanation for this observed variation in 
glioma frequencies might lie with the anatomical distribution 
of neuronal stem cell (NSC) population in the mammalian 
brain. The population of these cells is present and is prolif-
erative in the brain throughout the lifespan of an individual 
[11, 12]. Also, NSCs are believed to be a source of so-called 
‘brain cancer stem cells’ — cells that may give rise to gliomas 
[13–15]. Importantly, the largest migratory population of NSCs 
is found in the sub-ventricular zone (SVZ) in the wall of lateral 
ventricles [11, 12]. Lateral ventricles penetrate frontal, temporal 
and parietal lobes extensively, but the impinging of occipital 
lobe by posterior horn of lateral ventricle is limited. Further, in 
a rodent model, it has been demonstrated that there is a gradient 
of NSCs density and proliferative potential along the ventricular 
neuroaxis, with lower values found at the posterior (occipital) 
horn of lateral ventricles [16]. Thus, the differences in glioma 
frequencies among cortical lobes could be – at least partially 
– attributed to the degree of proximity between each lobe and 
active neuronal stem cell population. Such an interpretation is 
also consistent with the likely role of NSCs as a cell population 
where brain cancer stem cells originate. 
Our study found that tumours involving the temporal 
lobe are associated with poorer survival than other tumours, 
specifically in males. Previous reports on this association are 
contradictory, with one analysis similarly reporting poorer 
prognosis in temporal lobe gliomas and another study re-
porting improved survival in these patients [2]. This may be 
attributable to differences in patient demographics. Our study 
and the prior study that found poorer survival in temporal lobe 
patients were both conducted in the western United States, 
while the study that reported improved survival in these pa-
tients was conducted in Finland. Sufficient genetic and other 
clinical data is not available to determine to what extent this 
difference is attributable to variations in patient populations 
[9]. The gender differences in glioma outcomes are supported 
by previously published neuro-oncology and basic physiology 
research [17–19]. 
Our intention to analyse the molecular characteristics of 
these tumours was limited by the relatively recent prevalence 
of clinical genomic testing. We reviewed patient records from 
2008-2018, and less than 50% of cases had genetic data availa-
ble. While these tests have become a standard of care for most 
cancer patients, this was not the case in the 2000s. Given the 
decreasing cost and increasing availability of genomic assays, 
and the emerging importance of genomic information in clin-
ical care, it is increasingly important that neuro-oncologists 
strive to collect this information from as many of their patients 
as possible. As access to this data becomes more prevalent, 
researchers will become better equipped to re-visit the hypoth-
esis that molecular characteristics drive differences in tumour 
incidence and outcome in different regions of the brain. Our 
study did find that prognostically favourable IDH-1 muta-
tions were three times less likely in temporal lobe tumours 
compared to frontal lobe tumours [20]. Unfortunately, due 
to small sample sizes we were unable to conduct statistical 
analyses of this observation. 
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